A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma Interventions:   Biological: Nivolumab;   Biological: Ipilimumab Sponsor:   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials